FluoroAv45 Imaging Research-in Alzheimer's Disease

NCT ID: NCT01325259

Last Updated: 2016-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale: improving the early detection of AD at prodromal pre-dementia stages has become a major matter of concern. There is now an important body of literature stating that early isolated cognitive deficits (Mild Cognitive Impairment-MCI-) predict the risk of developing AD. Several biomarkers are now available : specific and sensitive neuropsychological assessments, morphometric evaluation of hippocampal volume and white matter changes by MRI, cerebrospinal fluid or plasma dosage of Ab fragments and tau proteins, assessment of brain glucose hypometabolism in temporo-parietal regions with PET \[F18\]FDG. However, PET imaging using labelled compounds specifically binding to APs has been suggested to improve the diagnostic reliability and to potentially help in shortening the delay until formal clinical diagnosis of AD. F18 AV45 is a new radiotracer which kinetics characteristics allows 10 to 15 minutes acquisition 50 to 60 minutes post injection.

Objectives: The primary objective of the study is to compare F18 AV45 cortical uptake in AD, MCI patients and Healthy Controls.

Secondary objectives will be to compare cortical uptake of F18 AV45 in MCI subject who will have convert toward dementia versus those who will not, at two year follow-up period, to compare level of 18F-AV45 cortical uptake with neuropsychological testing, PET FDG hypometabolism, ApoE genotype.

Method: Prospective multicentric study. 65 patients expected to enter the study.

Primary outcome measure: Standard Uptake Volume ratios.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alzheimer's disease

30 patients suffering from Alzheimer's disease

Group Type EXPERIMENTAL

neuropsychologic assessment

Intervention Type OTHER

Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI

[18F]AV-45 PET

Intervention Type RADIATION

intravenous injection of 4 MBq/kg of \[18F\]AV-45

18-FDG PET

Intervention Type RADIATION

intravenous injection of 100 to 120 MBq of FDG

MRI

Intervention Type OTHER

Magnetic Resonance Imaging

Mild Cognitive Impairment

20 patients suffering from Mild Cognitive Impairment

Group Type EXPERIMENTAL

neuropsychologic assessment

Intervention Type OTHER

Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI

[18F]AV-45 PET

Intervention Type RADIATION

intravenous injection of 4 MBq/kg of \[18F\]AV-45

18-FDG PET

Intervention Type RADIATION

intravenous injection of 100 to 120 MBq of FDG

MRI

Intervention Type OTHER

Magnetic Resonance Imaging

Control

15 subjects with no cognitive impairment

Group Type EXPERIMENTAL

neuropsychologic assessment

Intervention Type OTHER

Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI

[18F]AV-45 PET

Intervention Type RADIATION

intravenous injection of 4 MBq/kg of \[18F\]AV-45

18-FDG PET

Intervention Type RADIATION

intravenous injection of 100 to 120 MBq of FDG

MRI

Intervention Type OTHER

Magnetic Resonance Imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

neuropsychologic assessment

Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI

Intervention Type OTHER

[18F]AV-45 PET

intravenous injection of 4 MBq/kg of \[18F\]AV-45

Intervention Type RADIATION

18-FDG PET

intravenous injection of 100 to 120 MBq of FDG

Intervention Type RADIATION

MRI

Magnetic Resonance Imaging

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients suffering from Alzheimer's Disease (NINCDS-ADRDA) or from amnesic MCI
* 18 \< MMS \<= 28 for patients
* 28 \<= MMS for healthy volunteers
* study period \> 7 years
* native language : french
* signed informed consent
* affiliated to a social security system

Exclusion Criteria

* alcoholism in medical history
* diabetes
* arterial hypertension (180/100 and more)
* chronical pulmonary disease with hypoxis
* cranial traumatism with loss of consciousness \> 15 minutes
* severe depressive syndrome or anxiety
* psychiatric disease in medical history (excepted simple episodes of depression)
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vincent Camus

Role: PRINCIPAL_INVESTIGATOR

University Hospital of Tours

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

university hospital of CAEN

Caen, , France

Site Status

University Hospital of Lille

Lille, , France

Site Status

University Hospital of Toulouse

Toulouse, , France

Site Status

University Hospital of Tours

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHRN08-VC / FAIR AD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.